Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 1Recruiting 1Completed 1

Sponsor Class

INDUSTRY 3UNKNOWN 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × icaritin × Clear all
NCT05594927 2024-08-07

BESTPOP

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Recruiting
261 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03236649 2023-02-08

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Beijing Shenogen Biomedical Co., Ltd

Phase 3 Terminated
89 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01972672 2021-01-27

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Beijing Shenogen Biomedical Co., Ltd

Phase 2 Completed
70 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡